Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma (2024)

Hess, G., Dreyling, M., Oberic, L., Gine, E., Zinzani, P. L., Linton, K., Vilmar, A., Jerkeman, M., Chen, J. M. H., Ohler, A., Stilgenbauer, S., Thieblemont, C., Lambert, J., Zilioli, V. R., Sancho, J. M., Jimenez-Ubieto, A., Fischer, L., Eyre, T. A., Keeping, S., ... Salles, G. (2024). Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma. Leukemia and Lymphoma, 65(1), 14-25. https://doi.org/10.1080/10428194.2023.2268228

Hess, Georg ; Dreyling, Martin ; Oberic, Lucie et al. / Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma. In: Leukemia and Lymphoma. 2024 ; Vol. 65, No. 1. pp. 14-25.

@article{727ccf63bee4455b884859d21916a07f,

title = "Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma",

abstract = "The SCHOLAR-2 retrospective study highlighted poor overall survival (OS) with standard of care (SOC) regimens among patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) who failed a covalent Bruton tyrosine kinase inhibitor (BTKi). In the ZUMA-2 single-arm trial, brexucabtagene autoleucel (brexu-cel; autologous anti-CD19 CAR T-cell therapy) demonstrated high rates of durable responses in patients with R/R MCL who had previous BTKi exposure. Here, we compared OS in ZUMA-2 and SCHOLAR-2 using three different methods which adjusted for imbalances in prognostic factors between populations: inverse probability weighting (IPW), regression adjustment (RA), and doubly robust (DR). Brexu-cel was associated with improved OS compared to SOC across all unadjusted and adjusted comparisons. Hazard ratios (95% confidence intervals) were 0.38 (0.23, 0.61) for IPW, 0.45 (0.28, 0.74) for RA, and 0.37 (0.23, 0.59) for DR. These results suggest a substantial survival benefit with brexu-cel versus SOC in patients with R/R MCL after BTKi exposure.",

keywords = "brexucabtagene autoleucel, CAR T-cell therapy, indirect treatment comparison, mantle cell lymphoma, non-Hodgkin lymphoma, standard of care",

author = "Georg Hess and Martin Dreyling and Lucie Oberic and Eva Gine and Zinzani, {Pier Luigi} and Kim Linton and Adam Vilmar and Mats Jerkeman and Chen, {Jenny M.H.} and Anke Ohler and Stephan Stilgenbauer and Catherine Thieblemont and Jonathan Lambert and Zilioli, {Vittorio Ruggero} and Sancho, {Juan Manuel} and Ana Jimenez-Ubieto and Luca Fischer and Eyre, {Toby A.} and Sam Keeping and Park, {Julie E.} and Wu, {James J.} and Ana Nunes and John Reitan and Wade, {Sally W.} and Gilles Salles",

note = "Publisher Copyright: {\textcopyright} 2023 Kite Pharma. Published by Informa UK Limited, trading as Taylor & Francis Group.",

year = "2024",

month = jan,

day = "1",

doi = "10.1080/10428194.2023.2268228",

language = "English",

volume = "65",

pages = "14--25",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

number = "1",

}

Hess, G, Dreyling, M, Oberic, L, Gine, E, Zinzani, PL, Linton, K, Vilmar, A, Jerkeman, M, Chen, JMH, Ohler, A, Stilgenbauer, S, Thieblemont, C, Lambert, J, Zilioli, VR, Sancho, JM, Jimenez-Ubieto, A, Fischer, L, Eyre, TA, Keeping, S, Park, JE, Wu, JJ, Nunes, A, Reitan, J, Wade, SW & Salles, G 2024, 'Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma', Leukemia and Lymphoma, vol. 65, no. 1, pp. 14-25. https://doi.org/10.1080/10428194.2023.2268228

Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma. / Hess, Georg; Dreyling, Martin; Oberic, Lucie et al.
In: Leukemia and Lymphoma, Vol. 65, No. 1, 01.01.2024, p. 14-25.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma

AU - Hess, Georg

AU - Dreyling, Martin

AU - Oberic, Lucie

AU - Gine, Eva

AU - Zinzani, Pier Luigi

AU - Linton, Kim

AU - Vilmar, Adam

AU - Jerkeman, Mats

AU - Chen, Jenny M.H.

AU - Ohler, Anke

AU - Stilgenbauer, Stephan

AU - Thieblemont, Catherine

AU - Lambert, Jonathan

AU - Zilioli, Vittorio Ruggero

AU - Sancho, Juan Manuel

AU - Jimenez-Ubieto, Ana

AU - Fischer, Luca

AU - Eyre, Toby A.

AU - Keeping, Sam

AU - Park, Julie E.

AU - Wu, James J.

AU - Nunes, Ana

AU - Reitan, John

AU - Wade, Sally W.

AU - Salles, Gilles

N1 - Publisher Copyright:© 2023 Kite Pharma. Published by Informa UK Limited, trading as Taylor & Francis Group.

PY - 2024/1/1

Y1 - 2024/1/1

N2 - The SCHOLAR-2 retrospective study highlighted poor overall survival (OS) with standard of care (SOC) regimens among patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) who failed a covalent Bruton tyrosine kinase inhibitor (BTKi). In the ZUMA-2 single-arm trial, brexucabtagene autoleucel (brexu-cel; autologous anti-CD19 CAR T-cell therapy) demonstrated high rates of durable responses in patients with R/R MCL who had previous BTKi exposure. Here, we compared OS in ZUMA-2 and SCHOLAR-2 using three different methods which adjusted for imbalances in prognostic factors between populations: inverse probability weighting (IPW), regression adjustment (RA), and doubly robust (DR). Brexu-cel was associated with improved OS compared to SOC across all unadjusted and adjusted comparisons. Hazard ratios (95% confidence intervals) were 0.38 (0.23, 0.61) for IPW, 0.45 (0.28, 0.74) for RA, and 0.37 (0.23, 0.59) for DR. These results suggest a substantial survival benefit with brexu-cel versus SOC in patients with R/R MCL after BTKi exposure.

AB - The SCHOLAR-2 retrospective study highlighted poor overall survival (OS) with standard of care (SOC) regimens among patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) who failed a covalent Bruton tyrosine kinase inhibitor (BTKi). In the ZUMA-2 single-arm trial, brexucabtagene autoleucel (brexu-cel; autologous anti-CD19 CAR T-cell therapy) demonstrated high rates of durable responses in patients with R/R MCL who had previous BTKi exposure. Here, we compared OS in ZUMA-2 and SCHOLAR-2 using three different methods which adjusted for imbalances in prognostic factors between populations: inverse probability weighting (IPW), regression adjustment (RA), and doubly robust (DR). Brexu-cel was associated with improved OS compared to SOC across all unadjusted and adjusted comparisons. Hazard ratios (95% confidence intervals) were 0.38 (0.23, 0.61) for IPW, 0.45 (0.28, 0.74) for RA, and 0.37 (0.23, 0.59) for DR. These results suggest a substantial survival benefit with brexu-cel versus SOC in patients with R/R MCL after BTKi exposure.

KW - brexucabtagene autoleucel

KW - CAR T-cell therapy

KW - indirect treatment comparison

KW - mantle cell lymphoma

KW - non-Hodgkin lymphoma

KW - standard of care

UR - http://www.scopus.com/inward/record.url?scp=85174242231&partnerID=8YFLogxK

U2 - 10.1080/10428194.2023.2268228

DO - 10.1080/10428194.2023.2268228

M3 - Article

C2 - 37840282

AN - SCOPUS:85174242231

SN - 1042-8194

VL - 65

SP - 14

EP - 25

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 1

ER -

Hess G, Dreyling M, Oberic L, Gine E, Zinzani PL, Linton K et al. Indirect treatment comparison of brexucabtagene autoleucel (ZUMA-2) versus standard of care (SCHOLAR-2) in relapsed/refractory mantle cell lymphoma. Leukemia and Lymphoma. 2024 Jan 1;65(1):14-25. Epub 2023 Oct 16. doi: 10.1080/10428194.2023.2268228